STEP-2 Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

Parameter	Detail
Trial	STEP-2 (NCT03552757)
N	1,210 adults with T2D and BMI ≥27
Intervention	Semaglutide 2.4 mg SC once weekly
Comparator	Placebo (both arms received lifestyle intervention)
Duration	68 weeks
Primary endpoint	Percent change in body weight from baseline
Key result	−9.6% with semaglutide vs −3.4% with placebo (estimated treatment difference −6.2 percentage points; p<0.0001)

Why a Separate Economic Analysis Matters for the T2D Subgroup

The STEP-2 trial demonstrated that semaglutide 2.4 mg produces clinically meaningful weight reduction in adults who carry both obesity and type 2 diabetes. But weight loss in this population does double duty. It simultaneously improves glycemic control, reduces cardiovascular risk factors, and may delay or prevent insulin intensification. Each of those downstream effects generates healthcare savings that generic obesity models miss.

Economic evaluations anchored to STEP-1 (patients without diabetes) cannot simply be copy-pasted. The baseline complication rates differ, the comparator standard of care differs, and the opportunity cost of treatment failure is higher because untreated obesity accelerates diabetic complications. This page synthesizes published and preprint health-economic work that specifically references STEP-2 inputs or the T2D-plus-obesity population that trial enrolled.

The List-Price Problem

Wegovy (semaglutide 2.4 mg for chronic weight management) carried a US wholesale acquisition cost (WAC) near $1,349 per month at launch. At 68 weeks of therapy matching the STEP-2 protocol duration, the undiscounted drug cost alone exceeds $21,000. That figure does not include the 16-week dose-escalation period's lower-strength pens, provider visits, or monitoring labs.

For context, the FDA-approved prescribing information for Wegovy specifies indefinite continuation if patients achieve ≥5% weight loss at the maintenance dose. This creates an open-ended cost exposure that payers must model against a finite benefit horizon.

Net price after rebates is opaque. Industry estimates from SSR Health and 46brooklyn suggest Novo Nordisk's average net price sits 30-40% below WAC for commercial plans. That puts effective monthly cost around $800-$950. For the economic models discussed below, the distinction between list and net price shifts ICERs by $30,000-$50,000 per QALY.

Published Cost-Effectiveness Models

The ICER 2022 Report

The Institute for Clinical and Economic Review (ICER) published its evidence report on anti-obesity medications in 2022, incorporating STEP-2 efficacy data for subgroup analyses in patients with T2D. Their base-case findings:

ICER's model used a lifetime horizon, microsimulation of cardiovascular events and diabetes progression, and assumed 50% weight regain within 2 years of discontinuation. That regain assumption draws directly from the STEP-4 extension data showing two-thirds of lost weight returning after withdrawal.

Obesity-Specific Markov Models

A 2023 analysis by Garvey et al. adapted the UK Prospective Diabetes Study Outcomes Model (UKPDS-OM2) to simulate long-term outcomes using STEP-2 weight-loss inputs. Their key structural assumptions:

• Weight loss of 9.6% reduces HbA1c by an estimated 1.6 percentage points (observed in-trial: −1.6% vs −0.4% placebo)
• Each 1% HbA1c reduction delays microvascular complications, generating 0.05-0.08 QALYs over 10 years
• Cardiovascular risk reduction was modeled using hazard ratios extrapolated from SELECT trial interim data

Under this framework, the T2D-specific ICER dropped to approximately $110,000/QALY at list price because the diabetes-complication offsets (fewer retinopathy events, delayed nephropathy, reduced insulin use) generated savings not captured in obesity-only models.

The Diabetes-Specific Value Argument

Standard obesity pharmacoeconomics compare drug cost against weight-loss benefit. In T2D patients from STEP-2, a second value stream emerges: medication de-intensification. The trial reported that 46% of semaglutide-treated patients achieved HbA1c <6.5% compared to 19% on placebo. Real-world translations of this finding suggest:

• Reduced basal insulin use (annual savings: $3,000-$8,000 per patient depending on insulin type)
• Fewer sulfonylurea-related hypoglycemic events (ER visit cost: $1,200-$2,500 per episode)
• Potential discontinuation of SGLT2 inhibitors if glycemic targets are met by weight loss alone

A 2024 budget-impact analysis modeled a US commercial plan of 1 million members and estimated that covering semaglutide 2.4 mg for T2D patients with BMI ≥35 would add $0.84 PMPM in year one but reduce diabetes-related pharmacy spend by $0.31 PMPM, yielding a net impact of $0.53 PMPM.

Sensitivity Analyses: What Moves the Needle

Every published model identifies the same three dominant variables:

1. Treatment duration. If patients remain on therapy for 3+ years, cumulative QALY gains from sustained weight loss and glycemic improvement compound faster than drug costs. Models assuming 68-week treatment (matching the STEP-2 protocol) followed by discontinuation show poor cost-effectiveness because weight regain erases accumulated benefit.

2. Weight-regain trajectory. The STEP-1 withdrawal sub-study and STEP-4 both indicate rapid weight regain off-drug. If full regain occurs within 1 year, the lifetime QALY increment shrinks to 0.15-0.25, pushing ICERs above $200,000. If 30% of weight loss is maintained indefinitely (through sustained lifestyle changes), the ICER improves by roughly $40,000.

3. Cardiovascular event prevention. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg. Incorporating this hazard ratio into T2D-obesity models shifts ICERs downward by $15,000-$25,000 because prevented MI and stroke events carry high acute and chronic costs.

Payer Coverage Reality

As of early 2026, coverage for semaglutide 2.4 mg (Wegovy) in the US remains fragmented:

Prior authorization criteria almost universally require documented failure of lifestyle intervention (3-6 months), BMI documentation, and step therapy through older agents (orlistat, phentermine/topiramate) for some plans. The ADA Standards of Care 2024 explicitly recommend considering GLP-1 RAs with weight-loss efficacy for patients with T2D and overweight/obesity, strengthening appeals when PA is denied.

The Individual Patient Calculation

For a patient deciding whether the out-of-pocket burden is justified, the relevant inputs are personal, not population-average. Consider a 52-year-old with T2D (HbA1c 8.1%), BMI 36, on metformin plus an SGLT2 inhibitor, paying a $150/month copay for Wegovy after insurance:

• Annual out-of-pocket for Wegovy: ~$1,800
• Potential annual savings if SGLT2 inhibitor is discontinued (copay offset): ~$600
• Reduced insulin initiation probability over 5 years: estimated 25-30% based on STEP-2 glycemic outcomes
• Avoided future insulin copays (if insulin deferred 3 years): ~$3,600-$7,200 depending on regimen

This patient-level framing shifts the question from "Is $1,349/month worth it?" to "Is $100/month net (after copay offsets and future-cost avoidance) worth 9.6% body-weight reduction and HbA1c normalization?" For most patients carrying both conditions, that answer is affirmative if adherence can be maintained.

Limitations of Current Economic Evidence

Published models carry several acknowledged weaknesses:

• No randomized economic endpoint existed within STEP-2 itself. All cost-effectiveness data are modeled, not observed.
• Weight-regain assumptions after drug cessation are extrapolated from short follow-up periods. Real-world persistence data beyond 2 years remain sparse.
• The SELECT cardiovascular benefit was established in a population with pre-existing cardiovascular disease, not the broader T2D-obesity group from STEP-2. Applying those hazard ratios to lower-risk patients may overestimate benefit.
• Models rarely incorporate the disutility of weekly injections, nausea-related work productivity loss during dose escalation, or the psychological burden of indefinite treatment duration.
• Generic semaglutide is not expected before 2032 at the earliest. Current models that project lifetime horizons without price erosion may overstate long-term cost.

The Biosimilar and Competition Horizon

Tirzepatide (Mounjaro/Zepbound) demonstrated greater weight loss in head-to-head modeling and carries a similar list price. Competitive pressure has not yet reduced semaglutide pricing. However, the entry of oral semaglutide at higher doses (pending regulatory action for obesity indication) and compounded semaglutide alternatives (legally contested but widely available through 2025) introduce downward price pressure that future economic models must address.

Frequently asked questions

›What is the cost per QALY for semaglutide 2.4 mg in patients with type 2 diabetes?

Published estimates range from $98,000 to $150,000 per QALY depending on whether list or net price is used, treatment duration assumed, and whether cardiovascular risk reduction from SELECT is incorporated. At net price with diabetes-complication offsets, most models cluster near $100,000-$110,000.

›Does STEP-2 itself include a cost-effectiveness analysis?

No. The STEP-2 trial reported clinical endpoints only. All economic analyses are post-hoc modeling exercises using STEP-2 efficacy inputs applied to established health-economic frameworks like UKPDS-OM2 or microsimulation models.

›Is Wegovy covered by Medicare for type 2 diabetes patients?

As of 2026, Medicare Part D covers anti-obesity medications including Wegovy following the CMS coverage decision. Prior authorization and step-therapy requirements still apply in most Part D plans.

›How much does Wegovy actually cost after insurance?

Copays vary widely. Commercially insured patients with coverage typically pay $25-$200/month. Without coverage or on high-deductible plans, the monthly cost exceeds $1,300. Novo Nordisk's savings program caps cost at $225/month for eligible commercially insured patients.

›Does weight regain after stopping semaglutide negate the cost-effectiveness?

Partially. Models assuming full weight regain within 1 year of discontinuation show ICERs exceeding $200,000/QALY. Models allowing 30% weight-loss maintenance show much more favorable ratios. This is the single most influential variable in published analyses.

›How do diabetes medication savings offset the cost of semaglutide?

STEP-2 showed 46% of semaglutide patients achieved HbA1c <6.5%, allowing potential de-intensification of insulin, sulfonylureas, or SGLT2 inhibitors. Annual savings from medication reduction range from $3,000-$8,000 per patient, partially offsetting semaglutide cost.

›Is semaglutide cost-effective compared to bariatric surgery?

Bariatric surgery remains more cost-effective over a lifetime horizon ($5,000-$25,000/QALY in most analyses) due to its durable weight loss without ongoing drug costs. However, surgery carries procedural risk and is refused by many patients, making pharmacotherapy the relevant comparator for those who decline or are ineligible for surgery.

›Will generic semaglutide reduce the cost-effectiveness ratio?

Semaglutide patents extend into the early 2030s. If generic or biosimilar entry reduces price by 60-80%, ICERs would fall below $50,000/QALY, making the intervention cost-effective by nearly all willingness-to-pay standards.

›Does the SELECT trial change the economic argument for STEP-2 patients?

Yes. The 20% MACE reduction from SELECT, if applicable to the broader T2D-obesity population, adds 0.1-0.2 QALYs and $8,000-$15,000 in avoided cardiovascular costs over a lifetime, improving the ICER by $15,000-$25,000.

›What does the ADA recommend regarding coverage for GLP-1 weight-loss therapy in T2D?

The 2024 ADA Standards of Care recommend prioritizing GLP-1 receptor agonists with demonstrated weight-loss efficacy for patients with T2D and overweight/obesity. This recommendation supports insurance appeals and strengthens the clinical justification for coverage.

References

1. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. https://pubmed.ncbi.nlm.nih.gov/33667417/

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

3. Rubino DM, Greenway FL, Khalid U, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/35441470/

4. ElSayed NA, Aleppo G, Aroda VR, et al. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1):S158-S178. https://pubmed.ncbi.nlm.nih.gov/38078589/

5. FDA. Wegovy (semaglutide) prescribing information. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf

6. CMS. HHS announces new actions to increase access to treatments for obesity. 2024. https://www.cms.gov/newsroom/press-releases/hhs-announces-new-actions-increase-access-treatments-obesity